Table 1.
TCR-based clinical trials in metastatic uveal melanoma patients.
| NCT No. | Phase | Trial | Target | Sponsor/Collaborators | Status | Study Years | |
|---|---|---|---|---|---|---|---|
| HLA-Independent | Cellular-Based TCR Therapy | ||||||
| Genetically Unmodified T cells | |||||||
| NCT01814046 | II | Non-myeloablative lymohocyte depletion followed by transfer of autologous TILs with or without high-dose aldesleukin | Non-specific | National Institutes of Health Clinical Center (CC) | Results published [19] | March 2013–July 2017 | |
| NCT03467516 | II | Non-myeloablative lymohocyte depletion followed by transfer of autologous TILs with high-dose aldesleukin | Non-Specific | Udai Kammula; University of Pittsburgh | Recruiting (Results pending) | May 2018–December 2023 | |
| NCT04812470 | I | Preconditioning chemotherapy with melphlan followed by the transfer of autologous TILs administered via hepatic arterial infusion in addition with IL2 | Non-Specific | Sahlgrenska University Hospital; Vastra Gotaland Region; Miltenyi Biomedicine GmbH |
Not yet recruiting | November 2021–March 2028 | |
| HLA-Dependent | Genetically Modified T cells | ||||||
| NCT02654821 | I/II | Non-myeloablative lymohocyte depletion followed by transfer of autologous TILs | MART-1 | The Netherlands Cancer Institute | Results presented [20] | March 2012–January 2020 | |
| NCT02743611 | I/II | Transfer of autologous TCR-engineered T cells in addition to rimiducid | PRAME | Bellicum Pharmaceuticals | Results presented [21] | April 2017–July 2020 | |
| NCT03068624 | I | Transfer of autologous TCR-engineered T cells in addition to cyclophosphamide, aldesleukin, ipilimumab | SLC45A2 | MD Anderson Cancer Center; NCI | Recruiting (Results pending) | September 2017–September 2021 | |
| NCT04729543 | I/II | Pre-treatment with valproic acid and 5′ azacytidine followed by transfer of autologous TCR-engineered T cells | MAGE-C2 | Erasmus Medical Center | Recruiting (Results pending) | October 2020-October 2027 | |
| Non-Cellular TCR-Based Therapy | |||||||
| NCT01211262 | I | IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein | Gp100 | Immunocore Ltd. | Completed [22] | September 2010-July 2020 | |
| NCT02570308 | I/II | IMCgp100 using the intra-patient escalation dosing regimen | Gp100 | Immunocore Ltd. | Results presented [23] | February 2016–January 2021 | |
| NCT03070392 | III | Tebentafusp (IMCgp100) versus investigator choice (dacarbazine, ipilimumab, or pembrolizumab) in mUM | Gp100 | Immunocore Ltd. | Results published [24] | October 2017–March 2023 | |